Turkish IBD Organization's Position Statement on Inflammatory Bowel Disease Management Recommendations During COVID-19 Pandemic

TÖRÜNER M., Kalkan I. H., Akyuz F., Tezel A., ÇELİK A. F.

TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.32, sa.6, ss.488-492, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 32 Sayı: 6
  • Basım Tarihi: 2021
  • Doi Numarası: 10.5152/tjg.2021.280721
  • Dergi Adı: TURKISH JOURNAL OF GASTROENTEROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.488-492
  • Anahtar Kelimeler: Inflammatory bowel diseases, Crohn's disease, ulcerative colitis, COVID-19 pandemic, IMMUNE-RESPONSE, OPPORTUNISTIC INFECTIONS, VACCINE, THERAPY, CROHNS, RISK
  • İstanbul Üniversitesi Adresli: Hayır

Özet

The COVID-19 pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2, has resulted in high mortality and morbidity worldwide and is still a growing problem. Inflammatory bowel disease (IBD) is a chronic inflammatory disease for which a substantial number of patients are treated with immunosuppressive medications, either occasionally or long-term. Despite the accumulating evidence, there is still a lack of knowledge about the impact of COVID-19 on IBD patients, especially those who are under immunosuppressive treatment. Moreover, following the emergence of several COVID vaccines, there are concerns regarding vaccine effectiveness and possible side effects in such patients. In this context, we tried to briefly summarize the accumulating evidence and recommendations for the management of IBD in the context of the COVID-19 pandemic.